| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jun Cai, Wen Zhang, Zhenghui Yi, Weihong Lu, Zhiguo Wu, Jun Chen, Shunying Yu, Yiru Fang, Chen Zhan. Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms. Psychopharmacology. vol 230. issue 1. 2014-06-10. PMID:23660601. |
clinical observations indicate that atypical antipsychotics, especially clozapine, induce obsessive-compulsive (oc) symptoms in schizophrenia patients. |
2014-06-10 |
2023-08-12 |
Not clear |
| Yasuhiro Kaneda, Karuna Jayathilak, Herbert Meltze. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment. Psychiatry research. vol 178. issue 1. 2014-06-03. PMID:20452677. |
determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment. |
2014-06-03 |
2023-08-12 |
human |
| Yasuhiro Kaneda, Karuna Jayathilak, Herbert Meltze. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment. Psychiatry research. vol 178. issue 1. 2014-06-03. PMID:20452677. |
data from a prospective longitudinal study was used to test the hypotheses that (1) clozapine treatment would improve employment outcome in treatment-resistant schizophrenia or schizoaffective disorder patients, and (2) specific cognitive functioning at baseline and after treatment would predict work status at baseline and change in work status. |
2014-06-03 |
2023-08-12 |
human |
| Jayita K Deodhar, Kumar Prabhash, Jai P Agarwal, Pankaj Chaturved. Clozapine and cancer treatment: Adding to the experience and evidence. Indian journal of psychiatry. vol 56. issue 2. 2014-06-03. PMID:24891711. |
the judiciousness of the use of clozapine in patients with schizophrenia in clinical practice is brought to an even sharper focus when it has to be used in combination with other agents that cause myelosuppression, for example, chemotherapy and radiation treatment. |
2014-06-03 |
2023-08-13 |
Not clear |
| Yael Midbari, Tanya Ebert, Ira Kosov, Moshe Kotler, Abraham Weizman, Anca Ra. Hematological and cardiometabolic safety of clozapine in the treatment of very early onset schizophrenia: a retrospective chart review. Journal of child and adolescent psychopharmacology. vol 23. issue 8. 2014-05-26. PMID:24111981. |
hematological and cardiometabolic safety of clozapine in the treatment of very early onset schizophrenia: a retrospective chart review. |
2014-05-26 |
2023-08-12 |
Not clear |
| Yael Midbari, Tanya Ebert, Ira Kosov, Moshe Kotler, Abraham Weizman, Anca Ra. Hematological and cardiometabolic safety of clozapine in the treatment of very early onset schizophrenia: a retrospective chart review. Journal of child and adolescent psychopharmacology. vol 23. issue 8. 2014-05-26. PMID:24111981. |
in this retrospective chart review, we compared the safety of clozapine--as determined by hematological and cardiometabolic changes - to that of non-clozapine antipsychotics used in the treatment of childhood-onset schizophrenia (cos). |
2014-05-26 |
2023-08-12 |
Not clear |
| Josiane Bourque, Nadia Lakis, Julie Champagne, Emmanuel Stip, Pierre Lalonde, Olivier Lipp, Adrianna Mendre. Clozapine and visuospatial processing in treatment-resistant schizophrenia. Cognitive neuropsychiatry. vol 18. issue 6. 2014-05-21. PMID:23343453. |
clozapine and visuospatial processing in treatment-resistant schizophrenia. |
2014-05-21 |
2023-08-12 |
human |
| Yi Zhang, Meijuan Chen, Zhiguo Wu, Jun Chen, Shunying Yu, Yiru Fang, Chen Zhan. Association study of Val66Met polymorphism in brain-derived neurotrophic factor gene with clozapine-induced metabolic syndrome: preliminary results. PloS one. vol 8. issue 8. 2014-05-14. PMID:23967328. |
a total of 199 schizophrenia patients being treated with clozapine were divided into two groups, mets and non-mets, based on the diagnostic criteria of the national cholesterol education program's adult treatment panel iii. |
2014-05-14 |
2023-08-12 |
Not clear |
| Eric Latimer, Willy Wynant, Robin Clark, Ashok Malla, Erica Moodie, Robyn Tamblyn, Adonia Naid. Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Québec. Clinical schizophrenia & related psychoses. vol 7. issue 1. 2014-05-12. PMID:23367500. |
clozapine remains the antipsychotic of choice for people who, having met the criteria for a diagnosis of schizophrenia or a related psychotic disorder, do not respond adequately to other antipsychotic medications. |
2014-05-12 |
2023-08-12 |
Not clear |
| Fabiana Barzotti Kohlrausc. Pharmacogenetics in schizophrenia: a review of clozapine studies. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 35. issue 3. 2014-05-07. PMID:24142094. |
pharmacogenetics in schizophrenia: a review of clozapine studies. |
2014-05-07 |
2023-08-12 |
Not clear |
| Ofer Agid, Laura Schulze, Tamara Arenovich, Gautam Sajeev, Krysta McDonald, George Foussias, Gagan Fervaha, Gary Remingto. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 23. issue 9. 2014-05-01. PMID:23706529. |
data were gathered from a treatment algorithm implemented in patients with first-episode schizophrenia that employs two antipsychotic trials at increasing doses before clozapine. |
2014-05-01 |
2023-08-12 |
human |
| Andreia W P Hazewinkel, Jan P A M Bogers, Erik J Gilta. Add-on filgrastim during clozapine rechallenge unsuccessful in preventing agranulocytosis. General hospital psychiatry. vol 35. issue 5. 2014-04-25. PMID:23395419. |
we describe a patient with schizophrenia who developed agranulocytosis during treatment with clozapine and who did not respond to other antipsychotics. |
2014-04-25 |
2023-08-12 |
Not clear |
| Fabiana Barzotti Kohlrausch, Clarissa Severino-Gama, Maria Inês Lobato, Paulo Belmonte-de-Abreu, Angel Carracedo, Mara Helena Hut. The CYP1A2 -163C>A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patients. Psychiatry research. vol 209. issue 2. 2014-04-02. PMID:23601795. |
we evaluated two polymorphisms at cyp1a2 (*1c and *1f) in a sample of 108 european-derived patients with schizophrenia and their influence on the pro-convulsive effect of clozapine. |
2014-04-02 |
2023-08-12 |
Not clear |
| Adam Wysokiński, Iwona Kłoszewsk. Homocysteine levels in patients with schizophrenia on clozapine monotherapy. Neurochemical research. vol 38. issue 10. 2014-03-28. PMID:23873378. |
homocysteine levels in patients with schizophrenia on clozapine monotherapy. |
2014-03-28 |
2023-08-12 |
human |
| Adam Wysokiński, Iwona Kłoszewsk. Homocysteine levels in patients with schizophrenia on clozapine monotherapy. Neurochemical research. vol 38. issue 10. 2014-03-28. PMID:23873378. |
data for 24 subjects with schizophrenia treated with clozapine and 24 age- and sex-matched healthy volunteers was analyzed. |
2014-03-28 |
2023-08-12 |
human |
| Amy E Austin, Saskia S Guddat, Michael Tsokos, John D Gilbert, Roger W Byar. Multiple injuries in suicide simulating homicide: report of three cases. Journal of forensic and legal medicine. vol 20. issue 6. 2014-03-26. PMID:23910842. |
a high level of clozapine was detected on toxicological analysis of blood and a history of schizophrenia was reported. |
2014-03-26 |
2023-08-12 |
Not clear |
| Jessica L Gören, Mark Meterko, Sandra Williams, Gary J Young, Errol Baker, Chia-Hung Chou, Amy M Kilbourne, Mark S Baue. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatric services (Washington, D.C.). vol 64. issue 6. 2014-03-24. PMID:23450334. |
antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. |
2014-03-24 |
2023-08-12 |
Not clear |
| Pau Celada, Analía Bortolozzi, Francesc Artiga. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS drugs. vol 27. issue 9. 2014-03-19. PMID:23757185. |
postsynaptic 5-ht1a-rs in the prefrontal cortex (pfc) also appear important for the superior clinical effects of clozapine and other second-generation (atypical) antipsychotic drugs in the treatment of schizophrenia and related psychotic disorders. |
2014-03-19 |
2023-08-12 |
mouse |
| Pau Celada, Analía Bortolozzi, Francesc Artiga. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS drugs. vol 27. issue 9. 2014-03-19. PMID:23757185. |
the stimulation of 5-ht1a-rs in the pfc leads to the distal activation of the mesocortical pathway and to an increased dopamine release in pfc, an effect likely involved in the clinical actions of clozapine in negative symptoms and cognitive deficits in schizophrenia. |
2014-03-19 |
2023-08-12 |
mouse |
| Tetsuro Enomoto, Toshihiko Ito, Keisuke Sekine, Reiko Yasui, Yuko Ashizawa, Yoriyasu Uju, Tatsuro Hayakawa, Kazumi Tsukad. [Clinical experience with clozapine in 55 cases of treatment-resistant schizophrenia]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica. vol 115. issue 9. 2014-03-19. PMID:24228473. |
[clinical experience with clozapine in 55 cases of treatment-resistant schizophrenia]. |
2014-03-19 |
2023-08-12 |
Not clear |